News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major headlines emerged in the past hour; news flow was thin.
  • Global equity indices traded flat with little net movement.
  • U.S. Treasury yields showed minimal change across maturities.
  • Oil and gold prices were largely unchanged during the hour.
  • No significant economic data releases or central bank comments were published.
  • No new geopolitical or major corporate developments reported in the last hour.

Latest Articles

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market

Clearmind Medicine Inc., a clinical-stage biotech company focused on non-hallucinogenic neuroplastogen-derived therapeutics, announced filing a patent application in Hong Kong for innovative psychedelic compounds aimed at treating PTSD and other mental health disorders. This strengthens the company's global IP portfolio under its exclusive licensin…

3 E Network Finalizes Custom Edge AI SoC Architecture for Aladdin Robots, Delivering a Core Computing Foundation to Accelerate Commercialization

3 E Network Finalizes Custom Edge AI SoC Architecture for Aladdin Robots, Delivering a Core Computing Foundation to Accelerate Commercialization

3 E Network Technology Group Limited announced the completion of the architectural design and deployment planning for a custom Edge AI System-on-Chip (SoC) tailored for next-generation smart healthcare and eldercare robots developed in partnership with Aladdin Alaris AI. The custom chip addresses critical real-time responsiveness, privacy complianc…

Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

Standard BioTools announced the filing of a registration statement for its all-stock merger with Treeline Biosciences. The combined company, expected to operate as Treeline Biosciences Holdings, Inc. under the ticker TRLN, will have over $900 million in cash at closing to fund operations through 2029. Treeline brings a deep clinical-stage pipeline …

BrainsWay Announces Strategic Investment in Radial Health, Inc.

BrainsWay Announces Strategic Investment in Radial Health, Inc.

BrainsWay Ltd., a leader in noninvasive brain stimulation technologies, announced a $3 million minority equity investment in Radial Health, Inc., a company supporting a network of Brain Medicine clinics. This investment supports Radial's Series A financing and its plan to expand clinical infrastructure, reimbursement tools, and AI-based decision su…

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics announced FDA acceptance of its Biologics License Application for z-rostudirsen, an investigational treatment for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The FDA granted Priority Review with a target decision date of January 21, 2027. Z-rostudirsen demonstrated significant dystrophin production increases an…

Frontier Nuclear and Minerals Announces Board Renewal and Appointment of New Directors Ahead of Annual Meeting

Frontier Nuclear and Minerals Announces Board Renewal and Appointment of New Directors Ahead of Annual Meeting

Frontier Nuclear and Minerals Inc. announced the appointment of Joshua Girnun and Donal Carroll to its Board of Directors ahead of its August 2026 annual meeting. These appointments aim to bring enhanced expertise in metals and mining investment, corporate finance, and public company governance to support Frontier's growth in the nuclear fuel cycle…

Buy GGAL Ahead of a Credit Upswing: Cheap Book, High Optionality

Buy GGAL Ahead of a Credit Upswing: Cheap Book, High Optionality

Grupo Financiero Galicia (GGAL) trades near book value with a 3.8% yield and heavy exposure to an Argentine credit recovery. With market cap of $8.53B, improving credit demand under recent reform tailwinds and a relatively light float, GGAL offers an asymmetric risk/reward for active traders. We upgrade to Buy and lay out an actionable entry, stop …

IREN Signs $2.8bn in New Customer Contracts with Leading AI Developers, Raises 2026 ARR Target to over $4bn

IREN Signs $2.8bn in New Customer Contracts with Leading AI Developers, Raises 2026 ARR Target to over $4bn

IREN Limited announced a significant increase in its 2026 AI Cloud annualized run-rate revenue target from $3.7 billion to over $4 billion, backed by $2.8 billion in new multi-year cloud services contracts with leading AI developers including Microsoft and NVIDIA. The company's AI Cloud capacity is scaling rapidly, supported by strong customer dema…

Helport AI Completes Key Consumer Finance AI Labor Workflow, Advancing Toward Scalable Replication

Helport AI Completes Key Consumer Finance AI Labor Workflow, Advancing Toward Scalable Replication

Helport AI Limited announced a major advancement in its AI Labor platform with successful deployment and validation of customer acquisition workflows across multiple consumer lending products in Mexico. The company demonstrated its AI system's capability to perform complex customer acquisition tasks traditionally done by human experts, achieving st…

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Kamada Ltd. announced a three-year $50 million sales agreement to supply normal source plasma from its FDA-approved collection centers in Texas to a leading biopharmaceutical company specializing in plasma-derived therapies. The agreement validates Kamada's investment in U.S.-based plasma centers and supports its vertical integration and multi-year…

AIHS and CECC Form Joint Venture to Develop, Invest In, Construct and Operate AI Data Centers in the United States

AIHS and CECC Form Joint Venture to Develop, Invest In, Construct and Operate AI Data Centers in the United States

Senmiao Technology Limited (Nasdaq: AIHS) announced a joint venture with Constant Energy Construction Corp. to develop, invest in, construct, and operate AI data centers across the United States. This strategic move marks AIHS's expansion into the digital infrastructure sector, leveraging CECC's energy infrastructure and construction expertise alon…

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

Iridex Corporation announced the addition of its EndoProbe® Handpieces to the EyeProGPO product offering, making these disposable laser delivery devices available at preferred pricing to more than 4,300 EyeProGPO members. This expansion strengthens Iridex's collaboration with EyeProGPO and enhances ophthalmology practices' access to innovative reti…

NN, Inc. Expands Contract Manufacturing of Weapons Components, Secures New Awards with Leading Firearms Provider

NN, Inc. Expands Contract Manufacturing of Weapons Components, Secures New Awards with Leading Firearms Provider

NN, Inc. has successfully entered the US Tier 1 contract manufacturing market for firearm components, securing a multi-million dollar contract with a leading firearms provider. This new venture, part of NN's Defense & Electronics growth strategy, is expected to generate $12-15 million in sales starting Q3 2026 and ramp through 2028. The company's e…

Seer Urges Stockholders to Vote “FOR” Seer’s Highly Qualified Director Nominees on the BLUE Proxy Card TODAY

Seer Urges Stockholders to Vote “FOR” Seer’s Highly Qualified Director Nominees on the BLUE Proxy Card TODAY

Seer, Inc. is urging its shareholders to vote in favor of its board nominees ahead of the 2026 Annual Meeting, emphasizing the strong qualifications and independence of its directors. The company is countering a proxy challenge from activists seeking to replace several directors with candidates lacking proteomics and life sciences experience, which…

Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET

Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET

Nephros, Inc., a water technology company specializing in filtration solutions, announced that its CEO Robert Banks will present at the 'Health, Wellness & Longevity' virtual conference hosted by Maxim Group. The conference focuses on innovations in consumer health sectors including beverages, food, supplements, and longevity.

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

INmune Bio Inc. has successfully completed the transfer of its mesenchymal stromal cell manufacturing process to a commercial-ready stage, meeting MHRA, EMA, and FDA standards. This milestone supports the planned Phase 3 confirmation trial of its product Ebstrocel™, derived from the CORDStrom™ platform for treating recessive dystrophic epidermolysi…

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Harrow, a Nasdaq-listed ophthalmic disease management company, announced the presentation of three studies at the ASRS 2026 Annual Meeting that support its ocular anesthetic IHEEZO and biosimilar BYOOVIZ. Early data suggest IHEEZO improves patient experience with less pain and no increased risk of infection. Ongoing QUELL trial enrollment aims to p…

USA Rare Earth Announces Leadership Transition

USA Rare Earth Announces Leadership Transition

USA Rare Earth announces planned retirement of CEO Barbara Humpton effective October 1, 2026, with Thras Moraitis set to succeed her following the anticipated completion of the merger with Serra Verde by end of August 2026. Michael Blitzer appointed Executive Chairman immediately. The leadership change marks a shift from strategic buildup to operat…